{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:56Z","timestamp":1791219236077,"version":"4.1.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.2169\/internalmedicine.1981-18","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T17:34:39Z","timestamp":1547055279000},"page":"1263-1266","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis"],"prefix":"10.2169","volume":"58","author":[{"given":"Masashi","family":"Kono","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoriaki","family":"Komeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Minaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentarou","family":"Yamao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017."},{"key":"2","unstructured":"2. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872, 2007."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8: 49, 2017.","DOI":"10.3389\/fphar.2017.00311"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 44: 1063-1074, 2006.","DOI":"10.1002\/hep.21405"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Kulaksiz H, Heuberger D, Engler S. et al. Poor outcome in progressive sclerosing cholangitis after septic shock. Endoscopy 40: 214-218, 2008.","DOI":"10.1055\/s-2007-967024"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lindor KD, Wiesner RH, MacCarty RL, et al. Advances in primary sclerosing cholangitis. Am J Med 89: 73-80, 1990.","DOI":"10.1016\/0002-9343(90)90101-I"},{"key":"7","unstructured":"7. O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor\/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 2: 302-305, 1988."},{"key":"8","unstructured":"8. Kashima J, Okuma Y, Shimizuguchi R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67: 61-65, 2018."},{"key":"9","unstructured":"9. Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs 36: 144-146, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35: 529-536, 2017.","DOI":"10.1007\/s10637-017-0453-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kuraoka N, Hara K, Terai S, et al. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy 2018.","DOI":"10.1055\/a-0640-2392"},{"key":"12","unstructured":"12. Gelsomino F, Vitale G, D'Errico A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28: 671-672, 2017."},{"key":"13","unstructured":"13. Delis S, Triantopoulou C, Bakoyiannis A, et al. Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect. Dig Liver Dis 41: 72-77, 2009."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Batts KP. Ischemic cholangitis. Mayo Clin Proc 73: 380-385, 1998.","DOI":"10.1016\/S0025-6196(11)63706-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mart\u00edn AJ, Alfonso PG, Rup\u00e9rez AB, Jim\u00e9nez MM. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncol Lett 12: 727-730, 2016.","DOI":"10.3892\/ol.2016.4667"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.","DOI":"10.1056\/NEJMoa1200694"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Park SE, Lee SH, Ahn JS, et al. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol 13: 106-111, 2018.","DOI":"10.1016\/j.jtho.2017.10.011"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Aspeslagh S, Matias M, Palomar V, et al. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer 87: 65-74, 2017.","DOI":"10.1016\/j.ejca.2017.09.027"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sukari A, Nagasaka M, Abdallah N. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncol 80: 100-102, 2018.","DOI":"10.1016\/j.oraloncology.2018.03.011"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nadal R, Amin A, Geynisman DM, et al. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol 27: 1304-1311, 2016.","DOI":"10.1093\/annonc\/mdw160"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688, 2007.","DOI":"10.1158\/1078-0432.CCR-07-0187"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23: 6043-6053, 2005.","DOI":"10.1200\/JCO.2005.06.205"},{"key":"23","unstructured":"23. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg\/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12: 116, 2014."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/9\/58_1981-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T23:38:15Z","timestamp":1556926695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/9\/58_1981-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1981-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}